Evidence map›Paper›PMID 31382985›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.

Li Yi, Xingchen Zhou, Tao Li, Peidong Liu, Long Hai, Luqing Tong, Haiwen Ma, Zhennan Tao, Yang Xie, Chen Zhang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Biomolecules & biomedicine · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Li YiDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xingchen ZhouDepartment of Neurosurgery, The Second Affiliated Hospital of Bengbu Medical College, Anhui, 233000, China.
Tao LiDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Peidong LiuDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Long HaiDepartment of Radiation Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Henan, 450000, China.
Luqing TongDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Haiwen MaDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Zhennan TaoDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Yang XieDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Chen ZhangNeuro-Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.
Shengping YuDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xuejun YangDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China. ydenny@126.com.
Tianjin Medical University General Hospital · CNThe Second Affiliated Hospital of Bengbu Medical College · CNThe University of Texas MD Anderson Cancer Center · USZhengzhou University · CN

Funding

National Natural Science Foundation of China 81472352National Natural Science Foundation of China 81872063
6 · The paper itself

Abstract

backgroundGlioma initiating cells (GICs), also known as glioma stem cells (GSCs), play an important role in the progression and recurrence of glioblastoma multiforme (GBM) due to their potential for self-renewal, multiple differentiation and tumor initiation. In the recent years, Notch1 has been found to be overexpressed in GICs. However, the regulatory mechanism of Notch1 in the self-renewal and invasion ability of GICs remains unclear. This study aims to explore the effect of Notch pathway on self-renewal and invasion of GICs and the underlying mechanisms.

methodsBioinformatic analysis and immunohistochemistry (IHC) were performed to evaluate the expression of Notch1 and Hes1 in GBM samples. Immunofluorescent (IF) staining was performed to observe the distribution of Notch1 and CXCR4 in GBM and GICs. Both pharmacological intervention and RNA interference were employed to investigate the role of Notch1 in GICs self-renewal, invasion and tumor growth in vitro or in vivo. The crosstalk effect of Notch1 and CXCL12/CXCR4 system on GIC self-renewal and invasion was explored by sphere formation assay, limiting dilution assay and Transwell assay. Western blots were used to verify the activation of Notch1/CXCR4/AKT pathway in self-renewal, invasion and tumor growth of GICs. Luciferase reporter assay was used to testify the potential binding site of Notch1 signaling and CXCR4. The orthotopic GICs implantations were established to analyze the role and the mechanism of Notch1 in glioma progression in vivo.

resultsNotch1 signaling activity was elevated in GBM tissues. Notch1 and CXCR4 were both upregulated in GICs, compared to Notch1 positive glioma cells comprised a large proportion in the CD133+ glioma cell spheres, CXCR4 positive glioma cells which usually expressed Notch1 both and dispersed in the periphery of the sphere, only represent a small subset of CD133+ glioma cell spheres. Furthermore, downregulation of the Notch1 pathway by shRNA and MK0752 significantly inhibited the PI3K/AKT/mTOR signaling pathway via the decreased expression of CXCR4 in GICs, and weakened the self-renewal, invasion and tumor growth ability of GICs.

conclusionsThese findings suggest that the cross-talk between Notch1 signaling and CXCL12/CXCR4 system could contribute to the self-renewal and invasion of GICs, and this discovery could help drive the design of more effective therapies in Notch1-targeted treatment of GBMs.

Indexed as

Signal TransductionAnimalsBinding SitesCell Line, TumorCell MovementCell Self RenewalChemokine CXCL12Disease Models, AnimalGene ExpressionGliomaHeterograftsHumansImmunohistochemistryImmunophenotypingMiceModels, BiologicalChemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanNOTCH1 protein, humanProto-Oncogene Proteins c-aktReceptor, Notch1Receptors, CXCR4TOR Serine-Threonine KinasesCXCR4Glioma initiating cellsInvasionMigrationNotch1

Identifiers

PMID31382985
PMCPMC6683584
OpenAlexW2966839589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.